Intellipharmaceutics International Valuation

Q: What is the Fair Price of IPCI.H when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

IPCI.H (CA$0.08) is trading below our estimate of [[fair value]] (CA$0.69)

Is IPCI.H undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IPCI.H when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IPCI.H (CA$0.08) is trading below our estimate of fair value (CA$0.69)

Significantly Below Fair Value: IPCI.H is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IPCI.H?

Key metric: As IPCI.H is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for IPCI.H. This is calculated by dividing IPCI.H's market cap by their current revenue.
What is IPCI.H's PS Ratio?
PS Ratio	2.1x
Sales	US$904.95k
Market Cap	US$1.91m

IPCI.H key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.1x
Enterprise Value/EBITDA	-1.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does IPCI.H's PS Ratio compare to its peers?

The above table shows the PS ratio for IPCI.H vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	7.2x
CBDN CBD Global Sciences	4.5x	n/a	CA$2.2m
TILT TILT Holdings	0.01x	-1.5%	CA$3.9m
AREV AREV Life Sciences Global	15.5x	n/a	CA$2.9m
APLI Appili Therapeutics	8.6x	n/a	CA$4.2m
IPCI.H Intellipharmaceutics International	2.1x	n/a	CA$2.6m

Price-To-Sales vs Peers: IPCI.H is good value based on its Price-To-Sales Ratio (2.1x) compared to the peer average (6.9x).

Price to Sales Ratio vs Industry

How does IPCI.H's PS Ratio compare vs other companies in the CA Pharmaceuticals Industry?

25 Companies	Price / Sales	Estimated Growth	Market Cap
AYR.A Ayr Wellness	0.2x	2.5%	US$79.88m
IAN iAnthus Capital Holdings	0.1x	n/a	US$47.73m
TIUM.U Cansortium	0.2x	n/a	US$25.68m
ACRG.A.U Acreage Holdings	0.007x	n/a	US$17.58m

25 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: IPCI.H is expensive based on its Price-To-Sales Ratio (2.1x) compared to the Canadian Pharmaceuticals industry average (1.2x).

Price to Sales Ratio vs Fair Ratio

What is IPCI.H's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IPCI.H PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.1x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate IPCI.H's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Medexus Pharmaceuticals

CA$58.7m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.38

12.8%

60.8%

Verano Holdings

CA$722.2m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$1.98

-17.2%

-65.9%

Cresco Labs

CA$525.4m

Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States.

CA$1.67

-8.2%

-27.7%